# Atavistik Bio funding rounds and investors

As of 14 Oct 2026, Atavistik Bio has raised $120M across 1 verified round on record; latest: $120 million Series B led by Nextech Invest and The Column Group, announced 18 Dec 2025.

Atavistik Bio develops novel allosteric therapeutics for serious diseases, particularly targeting proteins involved in conditions like Hereditary Hemorrhagic Telangiectasia (HHT).

Website: https://atavistikbio.com  
Headquarters: Cambridge, Mass.  
Page: https://fireround.dev/companies/atavistikbio.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-12-18 | Series B | $120 million | Nextech Invest, The Column Group | Lux Capital, Regeneron Ventures | [atavistikbio.com](https://atavistikbio.com/companynews/atavistik-bio-raises-120-million-series-b-financing-to-advance-the-development-of-selective-allosteric-small-molecule-therapeutics-for-the-treatment-of-hereditary-hemorrhagic-telangiectasia-hht-and), [globenewswire.com](https://www.globenewswire.com/news-release/2025/12/18/3207561/0/en/atavistik-bio-raises-120-million-series-b-financing-to-advance-the-development-of-selective-allosteric-small-molecule-therapeutics-for-the-treatment-of-hereditary-hemorrhagic-telan.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.